17:33 EST Coherus Oncology (CHRS) files $150M mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Biosciences Earnings Call Highlights Strong Growth and Strategic Focus
- Optimistic Buy Rating for Coherus Biosciences Driven by Promising Oncology Pipeline and Strategic Focus
- Coherus Biosciences: Strategic Growth Potential and Strong Market Ambitions Justify Buy Rating
- Coherus Biosciences announces data from Phase 1b trial of CHS-114
- Coherus Oncology Reports Q3 2025 Financial Results